Dashboard Market News Pricing Contact Us
Search 100,000+ stocks...
English EN
Deutsch DE Español ES
Sign Up
Log in
Genmab A/S banner

Genmab A/S
CSE:GMAB

Watchlist Manager
Genmab A/S Logo
Genmab A/S
CSE:GMAB
Watchlist
Price: 2 264 DKK 0.18% Market Closed
Market Cap: kr141.2B
Write Note Create Alert Ask AI

Wall St Price Targets

GMAB Price Targets Summary
Genmab A/S

Wall Street analysts forecast GMAB stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for GMAB is 2 550 DKK with a low forecast of 1 414 DKK and a high forecast of 3 076.5 DKK.

GMAB Lowest Forecast
Wall Street Target
kr1 414
-38% Downside
GMAB Average Forecast
Wall Street Target
kr2 550
13% Upside
GMAB Highest Forecast
Wall Street Target
kr3 076.5
36% Upside
Lowest Forecast
Price Target
1 414 DKK
38% Downside
Average Forecast
Price Target
2 550 DKK
13% Upside
Highest Forecast
Price Target
3 076.5 DKK
36% Upside
Genmab A/S Competitors:
Price Targets

Revenue
Forecast

34% / Year
Past Growth
10% / Year
Estimated Growth
Estimates Accuracy
0%
Average Miss
34% / Year
Past Growth
10% / Year
Estimated Growth
Estimates Accuracy
0%
Average Miss

Over the last 13 years, the compound annual growth rate for Revenue has been 34%. The projected CAGR for the next 8 years is 10%.

What are analyst estimates?

Gross Profit
Forecast

N/A
Past Growth
7% / Year
Estimated Growth
Estimates Accuracy
3%
Average Beat
N/A
Past Growth
7% / Year
Estimated Growth
Estimates Accuracy
3%
Average Beat

The compound annual growth rate for Gross Profit over the next 8 years is 7%.

What are analyst estimates?

Operating Income
Forecast

N/A
Past Growth
10% / Year
Estimated Growth
Estimates Accuracy
4%
Average Beat
N/A
Past Growth
10% / Year
Estimated Growth
Estimates Accuracy
4%
Average Beat

The compound annual growth rate for Operating Income over the next 8 years is 10%.

What are analyst estimates?

Pre-Tax Income
Forecast

N/A
Past Growth
20% / Year
Estimated Growth
Estimates Accuracy
6%
Average Beat
N/A
Past Growth
20% / Year
Estimated Growth
Estimates Accuracy
6%
Average Beat

The compound annual growth rate for Pre-Tax Income over the next 3 years is 20%.

What are analyst estimates?

Net Income
Forecast

N/A
Past Growth
12% / Year
Estimated Growth
Estimates Accuracy
11%
Average Beat
N/A
Past Growth
12% / Year
Estimated Growth
Estimates Accuracy
11%
Average Beat

The compound annual growth rate for Net Income over the next 8 years is 12%.

What are analyst estimates?

Continue GMAB Research

Summary
GMAB intrinsic value, competitors valuation, and company profile.
DCF Valuation
GMAB stock valuation using Discount Cash Flow valuation method.
Relative Valuation
GMAB stock valuation using valuation multiples.
Wall St Estimates
GMAB price targets and financial estimates made by Wall Street analysts.
Profitability
Detailed analysis of the company's profitability.
Solvency
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
GMAB stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall St Estimates
Profitability
Solvency
Financials
Discount Rate
Other Genmab A/S listings:
NASDAQ • USD
GMAB
 OTC • USD
GNMSF
 F • EUR
GE9
 F • EUR
GE91
 SWB • EUR
GE9
 DUS • EUR
GE9
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.

What is GMAB's stock price target?
Price Target
2 550 DKK

According to Wall Street analysts, the average 1-year price target for GMAB is 2 550 DKK with a low forecast of 1 414 DKK and a high forecast of 3 076.5 DKK.

What is the Revenue forecast for Genmab A/S?
Projected CAGR
10%

Over the last 13 years, the compound annual growth rate for Revenue has been 34%. The projected CAGR for the next 8 years is 10%.

What is the Gross Profit forecast for Genmab A/S?
Projected CAGR
7%

The compound annual growth rate for Gross Profit over the next 8 years is 7%.

What is the Operating Income forecast for Genmab A/S?
Projected CAGR
10%

The compound annual growth rate for Operating Income over the next 8 years is 10%.

What is the Pre-Tax Income forecast for Genmab A/S?
Projected CAGR
20%

The compound annual growth rate for Pre-Tax Income over the next 3 years is 20%.

What is the Net Income forecast for Genmab A/S?
Projected CAGR
12%

The compound annual growth rate for Net Income over the next 8 years is 12%.

Back to Top
ALPHA SPREAD
Follow us
Join 358,300+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Valuation Backtest Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2026 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.